RECENT NEWS

QIAGEN has launched QIAsymphony Connect, the next generation of its widely adopted automated nucleic acid purification platform, at the 2025 AMP (Association for Molecular Pathology) annual meeting.

AI-powered virtual staining innovator Pictor Labs has announced the launch of ClearStain, its latest advancement designed to revolutionise molecular diagnostic workflows.

A research team from Trinity College Dublin has unveiled a groundbreaking new approach to vaccination that could redefine how we protect against respiratory infections.

Randox Toxicology has launched its first nitazenes array – a pioneering immunoassay designed to detect a broad spectrum of nitazene analogues with speed, accuracy, and clinical relevance.

New evaluation of NHS England’s emergency department opt-out testing has identified thousands of people living unknowingly with bloodborne viruses.

The Institute of Biomedical Science (IBMS), The Royal College of Pathologists (RCPath) and the Association for Laboratory Medicine (LabMed) have released a joint statement announcing a temporary pause in national quality assurance panel activities while a sustainable model is developed.

Clinical trial data demonstrate how Bio-Techne's spatial biology technology and Nucleai's AI-powered multi-modal platforms can identify predictive biomarkers in immunotherapy and targeted therapy-treated melanoma patients.

A new policy paper published by the Medicines and Healthcare products Regulatory Agency (MHRA) commits the UK to major reform in treatments for rare diseases, with a new rulebook for rare therapies being prepared for publication next year.

A new genomic method has identified 145 participants from the 100,000 Genomes Project with a complex genetic change linked to a rare condition, providing some with an explanation for their rare condition for the first time and others with a more precise diagnosis.

Immunohistochemistry firm Biocare Medical and Hamamatsu Corporation, an innovator in imaging technologies, have announced a strategic collaboration to accelerate innovation in the rapidly expanding field of spatial biology.

The influenza season has hit the NHS more than a month earlier than usual, with cases three times higher than this time last year; as shown by the UK Health Security Agency (UKHSA) latest surveillance data.

Ten pioneering health start-ups are tackling some of the world’s toughest healthcare challenges, from lung cancer to eye disease, at the Science and Technology Facilities Council’s (STFC) Daresbury Laboratory.

Professor Jacob George has been appointed as the first Chief Medical and Scientific Officer for the Medicines and Healthcare products Regulatory Agency (MHRA).

A new genetic test could be introduced into NHS screening pathways to target those most at risk of abdominal aortic aneurysm (AAA).

Roche has received the CE mark for its Elecsys Dengue Ag test – a high-throughput, fully automated immunoassay to be used as an aid in the diagnosis of an acute dengue virus infection.

Primerdesign (part of the Novacyt Group), a company focused on the design, manufacture, validation and supply of real-time PCR kits and reagents, has signed a distribution agreement with Scientific Laboratory Supplies (SLS).

EazeBio, a biotechnology company focused on developing scalable, patient-centred solutions, has announced a strategic partnership with the University of California, Santa Cruz (UC Santa Cruz) to co-develop an innovative cortisol biosensor for stress and metabolic health testing.

Lab Innovations, the UK’s biggest trade show event for the laboratory industry, has published a new report examining how artificial intelligence (AI) is being applied in UK laboratories.

Grundium, a specialist in digital imaging for pathology, and Washington University, St. Louis (WashU), have shown that Grundium’s technology matches the diagnostic accuracy of traditional methods for rapid on-site evaluation while decreasing turnaround times and improving patient care.

Image management system and workflow platform for digital pathology PathPresenter has announced that its Clinical Viewer has met the requirements of the EU In Vitro Diagnostic Regulation (IVDR 2017/746) and can now bear the CE mark. This certification clears it for clinical use in primary diagnosis in Europe.